Pharmaron Beijing Names CFO Li Shing Chung Gilbert as Employee Representative Director

Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has issued an update.

Pharmaron Beijing Co., Ltd. has appointed its chief financial officer and board secretary, Mr. Li Shing Chung Gilbert, as the employee representative director for the third session of its board, following his election at an employee representatives’ meeting held on 18 December 2025 in line with PRC company law and the company’s articles of association. Mr. Li, a long-serving finance executive with extensive experience in accounting, corporate finance, and M&A, will not receive separate remuneration for this board role and holds an indirect minority stake in the company through Pharmaron Holdings Limited, a move that further integrates employee representation into the boardroom without altering the existing shareholder approval process or control structure.

The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.

More about Pharmaron Beijing Co., Ltd. Class H

Pharmaron Beijing Co., Ltd. is a China-incorporated joint stock company listed in Hong Kong that operates in the pharmaceutical and life sciences sector, providing research, development and related services through a group structure with multiple subsidiaries. The company’s operations are overseen by a board composed of executive, non-executive, independent non-executive and employee representative directors, reflecting a corporate governance framework aligned with PRC company law and Hong Kong listing rules.

Average Trading Volume: 5,297,525

Technical Sentiment Signal: Buy

Current Market Cap: HK$51.92B

Learn more about 3759 stock on TipRanks’ Stock Analysis page.